Results 161 to 170 of about 12,025 (204)

Evaluation of inhaler satisfaction and medication adherence in patients with chronic obstructive pulmonary disease: A cross-sectional study. [PDF]

Medicine (Baltimore)
Kandasamy G, Subramani T, Orayj K, Almanasef M, Asiri R, Alshahrani AM, Vasudevan R, Alqifari SF, Ahmed R, Mani V, Alzaydani A, Sajith R, Abu-Elfotuh K, Prabahar K.   +13 more
europepmc   +1 more source

Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. [PDF]

Int J Chron Obstruct Pulmon Dis
Siler TM, Rheault T, Reyner D, MacDonald-Berko M, Davidson J, Rickard K.   +5 more
europepmc   +1 more source

Initial treatment of COPD with LABA-ICS or LABA-LAMA: real-world comparative effectiveness. [PDF]

BMJ Open Respir Res
Suissa S, Cherian M, Dell'Aniello S, Ernst P.   +3 more
europepmc   +1 more source

Rationale and Strategy for Switching to an All-Nebulization Protocol for In-Hospital Administration of Respiratory Medications. [PDF]

Hosp Pharm
Larson T, Caraway L, Chasteen B, Glick J.   +3 more
europepmc   +1 more source

Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.

JAMA Netw Open
Shanmugam H, Kesselheim AS, Liu ITT, Feldman WB, Rome BN.   +4 more
europepmc   +1 more source

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
openaire  

Some of the next articles are maybe not open access.

Related searches:

Current long-acting muscarinic antagonists for the treatment of asthma

Expert Opinion on Pharmacotherapy, 2021
The role of long-acting muscarinic antagonists (LAMAs) is well established in uncontrolled asthma, but not in milder stages.This review examines the main randomized controlled trials (RCTs) that have investigated LAMAs administered as monotherapy or in combination to asthmatic patients, according to the different phenotypes.
Ora J., Calzetta L., Ritondo B. L., Matera M. G., Rogliani P.   +4 more
openaire   +3 more sources

Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010
ABSTRACT Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium.
Jørgen Vestbo, Claus Vogelmeier, Esther Garcia Gil   +2 more
exaly   +5 more sources